Activating pyruvate kinase R

US12128035B2 · kind B2 · utility

Assignee

• Novo Nordisk Health Care AG · CH

Inventors

• Anna Ericsson · Keyano, CA
• Neal Green · Newton, US
• Gary Gustafson · Ridgefield, US
• David R. Lancia, Jr. · Boston, US
• Gary Marshall · Chicago, US
• Lorna Helen Mitchell · Auckland, NZ
• David Richard · Monroe, US
• Zhongguo Wang · Lexington, US
• Sanjeev Forsyth · Milton, US
• Patrick F. Kelly · Concord, US
• Madhu Mondal · Winchester, US
• Maria Ribadeneira · Cambridge, US
• Patricia Schroeder · Somerville, US

Key dates

• Filing date: Mar 18, 2022
• Grant date: Oct 29, 2024
• Expiry date: Mar 18, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P9/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.